Artificial intelligence tools developed at Case Western Reserve University in Cleveland are going to be put to the test in the fight against cancer. The computational-imaging tools hope to accurately predict whether individual cancer patients will respond to immunotherapy. The technology is the brainchild of Anant Madabhushi, the F. Alex Nason Professor II of Biomedical Engineering at Case Western.
Two pharmaceutical companies will test Madabhushi’s tech in clinical trials: AstraZeneca and Bristol-Myers Squibb. Using machine learning, researchers will seek and identify changes in patterns in CT scans of lung cancer patients before and after immunotherapy. Researchers have also had luck predicting response to gynecologic cancers. “This is an important step in not only validating our research, but in further advancing efforts to get the right treatment to the patients who will benefit the most,” Madabhushi said.